Literature DB >> 17624579

Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells.

Naoki Ishiguro1, Masanobu Oyabu, Toshihiro Sato, Tomoji Maeda, Hironobu Minami, Ikumi Tamai.   

Abstract

PURPOSE: We investigated whether gefitinib, an anticancer agent, inhibits phosphatidylcholine (PC) biosynthesis and choline uptake by alveolar epithelial type II cells.
MATERIALS AND METHODS: Uptake of choline and PC biosynthesis were examined in vitro, using human alveolar epithelia-derived cell line A549 and rat alveolar type (AT) II cells as models.
RESULTS: Gefitinib reduced the incorporation of [3H]choline into PC in A549 and rat ATII cells. The uptake of [3H]choline by A549 and rat ATII cells was concentration-dependent, and the Km values were 15.0 and 10-100 microM, respectively. The uptake of [3H]choline by A549 and rat ATII cells was weakly Na+-dependent, and inhibited by hemicholinium-3. RT-PCR revealed expression of choline transporter-like protein (CTL)1 and organic cation transporter (OCT)3 mRNAs in both cells. The choline uptake by A549 and rat ATII cells was strongly inhibited by gefitinib with the IC50 value of 6.77 microM and 10.5 microM, respectively.
CONCLUSIONS: Our results demonstrate that gefitinib reduces PC biosynthesis via inhibition of cellular choline uptake by A549 and rat ATII cells, which is mainly mediated by CTL1, resulting in abnormality of lung surfactant that can be one of mechanisms of the interstitial lung disease associated with gefitinib.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624579     DOI: 10.1007/s11095-007-9362-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  39 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Identification and characterization of the high-affinity choline transporter.

Authors:  T Okuda; T Haga; Y Kanai; H Endou; T Ishihara; I Katsura
Journal:  Nat Neurosci       Date:  2000-02       Impact factor: 24.884

3.  Selection and characterization of the choline transport mutation suppressor from Torpedo electric lobe, CTL1.

Authors:  Seana O'Regan; François-Marie Meunier
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

4.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 5.  ABCA3 deficiency: neonatal respiratory failure and interstitial lung disease.

Authors:  Janine E Bullard; Susan E Wert; Lawrence M Nogee
Journal:  Semin Perinatol       Date:  2006-12       Impact factor: 3.300

6.  A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells.

Authors:  M Lieber; B Smith; A Szakal; W Nelson-Rees; G Todaro
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

7.  Sodium-dependent and -independent choline uptake by type II epithelial cells from rat lung.

Authors:  G D van Rossum; C A Boyd
Journal:  J Membr Biol       Date:  1998-03-15       Impact factor: 1.843

8.  Cloning and characterization of two human polyspecific organic cation transporters.

Authors:  V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell
Journal:  DNA Cell Biol       Date:  1997-07       Impact factor: 3.311

9.  United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Authors:  Martin H Cohen; Grant A Williams; Rajeshwari Sridhara; Gang Chen; W David McGuinn; David Morse; Sophia Abraham; Atiqur Rahman; Chenyi Liang; Richard Lostritto; Amy Baird; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

10.  An improved method for isolating type II cells in high yield and purity.

Authors:  L G Dobbs; R Gonzalez; M C Williams
Journal:  Am Rev Respir Dis       Date:  1986-07
View more
  7 in total

1.  Choline transport links macrophage phospholipid metabolism and inflammation.

Authors:  Shayne A Snider; Kaitlyn D Margison; Peyman Ghorbani; Nicholas D LeBlond; Conor O'Dwyer; Julia R C Nunes; Thao Nguyen; Hongbin Xu; Steffany A L Bennett; Morgan D Fullerton
Journal:  J Biol Chem       Date:  2018-06-07       Impact factor: 5.157

Review 2.  Choline transport for phospholipid synthesis: An emerging role of choline transporter-like protein 1.

Authors:  Vera Hedtke; Marica Bakovic
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-18

3.  Palmitic acid and oleic acid differentially regulate choline transporter-like 1 levels and glycerolipid metabolism in skeletal muscle cells.

Authors:  Laila Cigana Schenkel; Marica Bakovic
Journal:  Lipids       Date:  2014-06-28       Impact factor: 1.880

4.  Review of the treatment of non-small cell lung cancer with gefitinib.

Authors:  Takuya Araki; Hideaki Yashima; Kimihiro Shimizu; Tohru Aomori; Tadahiro Hashita; Kyoichi Kaira; Tomonori Nakamura; Koujirou Yamamoto
Journal:  Clin Med Insights Oncol       Date:  2012-12-06

Review 5.  Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis.

Authors:  Olivier Burgy; Sabrina Loriod; Guillaume Beltramo; Philippe Bonniaud
Journal:  Cells       Date:  2022-04-03       Impact factor: 6.600

Review 6.  The epithelial cholinergic system of the airways.

Authors:  W Kummer; K S Lips; U Pfeil
Journal:  Histochem Cell Biol       Date:  2008-06-20       Impact factor: 4.304

7.  Lipids at the crossroad: Shaping biological membranes heterogeneity defines trafficking pathways.

Authors:  Yohann Boutté
Journal:  PLoS Biol       Date:  2018-02-26       Impact factor: 8.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.